1
ARCHITECT® HIV Ag/Ab Combo:
Moving HIV Diagnostics Forward in
the U.S.
Catherine Brennan, Ph.D.
Research Fellow
Infectious Diseases Research
Abbott Diagnostics
2
Agenda
ARCHITECT HIV Ag/Ab Combo Assay
What is the Combo assay
Performance characteristics
Importance of detecting acute HIV infection
Early data from US laboratories
3
ARCHITECT® HIV Ag/Ab Combo
Chemiluminescent microparticle immunoassay for in vitro diagnostic use.
Simultaneous qualitative detection of HIV p24 antigen and antibodies to HIV-1 group M and group O and/or HIV-2 in human serum and plasma (EDTA and heparin)
Intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection, including acute or primary infection
An ARCHITECT HIV Ag/Ab Combo reactive result does not distinguish between the detection of HIV-1 p24 antigen, HIV-1 antibody, or HIV-2 antibody
May be used to aid in the diagnosis of HIV-1/HIV-2 infection in pediatric subjects (i.e. children as young as 2 years of age) and in pregnant woman
Not intended for use in screening blood or plasma donors. However can be used as a blood donor screening assay in urgent situations where traditional licensed blood donor screening assays are unavailable or their use is impractical
ARCHITECT HIV Ag/Ab Package Insert 34-5589/R1
4
ARCHITECT Instrument
Fully-automated, random-access
(no Control brackets)
Stat capability
HIV Combo assay:
29 minute time to first result
>150 tests per hour on i2000SR
>50 tests per hour on i1000SR
ARCHITECT HIV Ag/Ab Package Insert and ARCHITECT Operations Manual
5
ARCHITECT HIV Ag/Ab Combo
First 4th generation HIV Ag/Ab Combination assay
approved in United States; FDA approval on June
18, 2010
>100,000 data points to evaluate • Detection of HIV antibodies to HIV-1 group M (including diverse
subtypes), HIV-1 group O, and HIV-2
Detection of HIV p24 antigen (diverse virus isolates,
seroconversion panels, Ab negative specimens)
Specificity and sensitivity in low and high risk populations,
pregnant females, and pediatrics
Overall specificity: 99.77% (95% CI: 99.62-99.88%)
HIV antibody sensitivity:100% (95% CI: 99.63-
100.00%)
HIV p24 Ag analytical sensitivity: 18.39 pg/mL (range
17.80-19.68 pg/mL)
ARCHITECT HIV Ag/Ab Combo Package Insert
6
What is Acute Phase of HIV Infection?
Fiebig et al AIDS, 17:1871-1879 (2003)
Absence of HIV specific antibodies
Rapid rise in plasma viremia
Acute viral syndrome: fever, rash, diarrhea, fatigue, headache –
opportunity for HIV testing
Detect AHI by NAT or p24 antigen
0 10 20 30 40 50 60 70 80 90 100
HIV RNA
(plasma)
HIV p24 Ag
Day post infection
Anti-HIV Ab
Appearance of markers of HIV infection
AHI
7
Why is Detection of AHI Important?
AHI makes a significant contribution to the ongoing epidemic
May account for 15-50% of new infections
During the acute phase, substantially increased risk of transmission
Estimated 28-fold increase compared to chronic phase
Period of high viremia
Virus appears to be more infectious
Individual unaware of infection status
Often test negative
8
HIV Combo Acute HIV Infection Studies
Dr J. Stekler, University of Washington, Seattle
Dr. M. Pandori, San Francisco Department of Public Health
Dr. S. Eshleman, Johns Hopkins University, Baltimore
Dr. P. Patel, CDC, Atlanta
K. Delaney, CDC, Atlanta
Dr. M. Owen, CDC, Atlanta
Dr. L. Wesolowski, CDC, Atlanta
9
Acute HIV Infection Studies
Basic testing strategy:
Specimens screened with an HIV antibody test
All negative specimens tested by HIV NAT
Define acute HIV infection:
Specimens detected utilizing HIV NAT
Stored specimens blinded and sent to Abbott for Combo testing
Included HIV antibody positive, Western blot confirmed specimens and
HIV negative specimens
Used ARCHITECT HIV Ag/Ab Combo (CE marked version; 4J27)
10
Seattle Study Stekler JD, et al, Clin Infectious Diseases 2009; 49:444-453
MSM population – high risk, frequent testing
Specimens collected at Public Health-Seattle and King County
2003-2008 specimens screened N=14,005
HIV antibody positive N=328 (2.3%)
HIV Ab-/RNA+ (acute) N=36 (0.3%)
NAT algorithm increased yield of HIV infection by 11%
Median time from collection to report of NAT+ result: 16-19 days
11
Seattle Combo Results
16 of 36 acute HIV
specimens available for
ARCHITECT HIV Combo
testing
HIV Combo detected 15 of
16 (94%)
HIV RNA for Combo
negative: 4,946 copies/mL
Median HIV RNA for Combo
positive: 4.5 million
copies/mL
Specimen
ID
HIV-1 EIA
s/co
ARCHITECT
Combo s/co
HIV RNA
copies/mL*
47 0.18 0.2 4,946
9 0.4 2.17 133,120
10 nd 2.68 284,605
12 nd 5.09 483,329
11 0.3 9.85 1,133,033
45 0.24 10.36 637,151
16 0.08 21.32 1,714,915
42 0.02 36.31 5,678,616
41 0.59 36.43 4,510,685
43 0.12 42.75 5,678,616
44 0.25 45.87 4,510,685
48 0.14 54.55 8,795,135
46 0.19 80.68 22,092,380
14 0.6 101.6 26,560,883
13 0.5 108.9 6,519,924
15 0.4 463.4 >90,000,000 *RealTime HIV-1 assay performed using
residual specimen volume
12
Seattle Conclusions
Extrapolation of Combo results to entire study population:
Testing Strategy % HIV Infections Detected
EIA/NAT algorithm 100
HIV Combo 99.4
1st/2nd Gen EIA 90
OraQuick Rapid 80
The sensitivity of ARCHITECT HIV Combo greatly reduces or
eliminates the need for NAT even in a high risk, high prevalence
population.
Combo assay could shorten time to report results. For HIV prevention
and partner notification, CDC target for time to report an HIV positive
result is <72 hours.
13
ARCHITECT HIV Combo Detects Acute HIV Infections
*Site used individual NAT instead of pooled NAT
Site # AHI Combo
tested
# AHI Combo
detected
Seattle (Stekler, CID 2009; 49:444-453) 16 15 (94%)
San Francisco (Pandori, JCM 2009; 47:2639-2642) 64 57 (89%)
EXPLORE (Eshleman, JAIDS 2009; 52:121-124) 21 13 (62%)*
CDC AHI Study (Patel, Arch Int Med 2010; 170:66-74) 38 34 (89%)
CDC Rapid Study (Delaney, CROI 2009, poster 997) 17 13 (76%)*
Total 156 132 (85%)
Combo assay detected 85% of acute HIV infections
AHI not detected by HIV Combo: 724 - 21,548 RNA copies/mL
AHI detected by HIV Combo: 30,734 - >10,000,000 copies/mL
14
ARCHITECT HIV Combo Seroconversion Sensitivity
Seroconversion Panel HIV 9079 (Vendor data: ZeptoMetrix Corp)
Based on 31 panels, Combo reduced window period a median of 7 days
relative to 3rd generation Ab assay; range 0-20 days1
Roche Cobas ARCHITECT BioRad
Days RNA copies/mL Combo BioRad 1/2/O Unigold Multispot Oraquick HIV-1 WB
0 not detected 0.12 0.648 - - -
2 not detected 0.07 0.133 - - -
9 not detected 0.15 2.116 - - -
18 not detected 0.10 0.580 - - -
20 not detected 0.10 0.177 - - -
28 not detected 0.11 0.222 - - -
33 not detected 0.08 0.102 - - -
35 >400 0.15 0.352 - - -
40 271,000 3.58 0.287 - - - -
42 >750,000 23.85 0.119 - - - -
47 >750,000 43.06 1.065 - - - -
49 >750,000 68.68 2.679 - - - ind
55 211,000 34.81 9.689 - + - ind
57 46,300 3.78 9.949 - + - ind
62 11,000 4.13 10.239 - + - +
64 11,500 8.38 10.239 - + - +
69 21,700 12.83 10.239 - + - +
71 20,400 13.51 10.239 - + - +
76 18,800 19.63 10.239 + + + +
78 26,500 20.99 10.239 + + + +
83 18,700 24.17 10.239 + + + +
85 29,600 24.23 10.239 + + + +
90 23,800 25.15 10.239 + + + +
92 21,100 27.52 10.239 + + + +
97 15,400 29.39 10.239 + + + +
1ARCHITECT HIV Ag/Ab Combo Package Insert
15
Reduction in Seroconversion Window Period
Fiebig et al, AIDS 2003; 17:1871-1879 Owen et al, J Clin Micro 2008; 46:1588-1595
Kleinman et al, Transfusion 2009; 49:2454-2489 Patel et al, Arch Int Med 2010; 170:66-74
1st Gen HIV Ab
3rd Gen HIV Ab
0 10 20 30 40 50 60 70 80 90 100
HIV RNA
(plasma)
17
22
HIV p24 Ag
4th Gen HIV Ag/Ab
Day post infection
Anti-HIV Ab
35 1st Gen Ab
3rd Gen Ab
4th Gen Ag/Ab
16
Erie County Medical Center Buffalo, NY:
Increased HIV Testing and Identification of AHI
Implementation of NYS law resulted in 5-fold increase in HIV tests performed
Tested 3601 patients w/ ARCHITECT HIV Combo assay:
31 confirmed HIV infections (0.9%)
6 newly diagnosed chronic HIV infections
1 diagnosed acute HIV infection
Specificity: 99.92%
AHI case:
37 year old with acute viral syndrome came to emergency room
Reactive for HIV: ARCHITECT HIV Combo, HIV-1 RNA
Nonreactive for HIV: 3rd generation EIA, rapid test, western blot
Myers JB, et al., 27th Clinical Virology Symposium, May 2011, Daytona Beach FL
17
ARCHITECT HIV Combo: The U.S. Experience
Avera McKennan Hospital, Sioux Falls, SD
3533 ARCHITECT HIV Combo tests run in 7 months
16 confirmed HIV infections; prevalence 0.45%
4 newly diagnosed HIV infections
3 acute HIV infections
48 minute average turn around time for HIV Combo result (from time of draw)
Specificity: 99.86%
Dallas-Fort Worth, TX
Tested 220 specimens from patients being screened for HIV
Compare ARCHITECT Combo to comparator tests
Combo detected 4 AHI not detected by comparator plus 1 recent infection with indeterminant Western blot
Dr L Serrano, Abbott Workshop, AACC 2011.
Wians FH, et al., Labmedicine (2011) 42:523-535.
18
ARCHITECT HIV Ag/Ab Combo: Conclusions
HIV Combo detects HIV infections during the acute, recent, and
established phases of infection.
Substantial improvement over HIV Ab immunoassays
Sensitive Ag and Ab detection across HIV subtypes/groups
High specificity (reduced cost associated with false-positives)
Fully automated, random access, high through-put
Time to first result: 29 minutes
Early implementation of ARCHITECT HIV Combo assay has
demonstrated benefits of the assay both high and low prevalence
settings
19
Publications on ARCHITECT HIV Combo
1. Ly TD, et al, J Virol Meth 2007, 143:86-94. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays?
2. Pandori MW, et al, J Clin Micro 2009, 47:2639-2642. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high risk setting.
3. Stekler JD, et al Clin Infect Dis 2009, 49:444-453. HIV testing in a high incidence population: is antibody testing alone good enough?
4. Eshleman SH, et al, J Acquir Immune Defic Syndr 2009, 52:121-124. Detection of individuals with acute HIV-1 infections using the ARCHITECT HIV Ag/Ab Combo assay.
5. Patel P, et al, Arch Intern Med 2010, 170:66-74. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008.
6. Bischof JJ, et al AIDS 2011, 25:1927-1929. Prospective study of the ARCHITECT HIV Ag/Ab Combo 4th generation assay to detect HIV infection in STI clinics.
7. Wians FH, et al, Labmedicine 2011, 42:523-535. Evaluation of four qualitative third-generation HIV antibody assays and the fourth-generation Abbott HIV Ag/Ab Combo test.
8. Masciotra S, et al, J Clin Virol 2011, dio:10.1016/j.jcv.2011.09.011. Evaluation of alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections.
B. Branson, CDC: APHL Webcast, Nov 15, 2011: HIV Diagnostics: New Tests and New Algorithms